Early Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics

Early Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics

Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.

Learning Objectives

  • Pulmonary arterial hypertension as a clinical condition
  • Applying proteomics to risk stratification
  • Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition

Christopher Rhodes, MA, Cantab, PhD

Christopher Rhodes, MA, Cantab, PhD

Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London

Martin R. Wilkins

Martin R. Wilkins

Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London

Early Detection, Risk Stratification, and Drug Target Identification in Pulmonary Arterial Hypertension with Plasma Proteomics

A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins

Share with colleagues

More webinars

WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program

How SomaLogic Technologies can give your research programs an edge

Learn more

WebinarA proteomics signature of NASH

There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.

Learn more

WebinarUsing non-hypothesized based approaches for biomarker development

Current biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury or concussion. Therefore, more accurate diagnostic markers are needed for sport-related concussion (SRC).

Learn more